CJC-1295
Also known as: CJC-1295 DAC, CJC-1295 without DAC, Modified GRF 1-29
Long-acting growth hormone releasing hormone analog — sustained GH pulses for muscle growth, fat loss, and recovery.
Molecular structure image coming soon
Research use only. Not FDA-approved. May affect blood glucose. Monitor IGF-1 levels with medical supervision.
Overview
CJC-1295 is a synthetic analog of Growth Hormone Releasing Hormone (GHRH). The DAC (Drug Affinity Complex) version has an extended half-life of 6–8 days due to its ability to bind albumin, while the non-DAC version (Modified GRF 1-29) has a shorter half-life of ~30 minutes. Both stimulate the pituitary gland to release growth hormone in natural pulsatile patterns.
Mechanism of Action
CJC-1295 binds to GHRH receptors in the pituitary gland, stimulating growth hormone synthesis and secretion. The DAC version extends activity through covalent albumin binding. This results in increased IGF-1 levels which mediate many of GH's anabolic and lipolytic effects.
Use Cases
- ✓Lean muscle mass development
- ✓Body fat reduction
- ✓Improved sleep quality and recovery
- ✓Anti-aging protocols
- ✓Growth hormone deficiency (under medical supervision)
- ✓Bone density improvement
Research Summary
Clinical studies have demonstrated that CJC-1295 significantly increases plasma GH and IGF-1 concentrations in healthy adults. A Phase I/II trial showed sustained GH elevation for up to 14 days with a single injection of the DAC version. Commonly paired with ipamorelin for synergistic GH release.
Typical Dosing
CJC-1295 DAC: 1–2 mg per week. Modified GRF 1-29: 100–200 mcg 2–3x daily, often combined with ipamorelin.
Administration
Research Chemical
Research use only. Not FDA-approved. May affect blood glucose. Monitor IGF-1 levels with medical supervision.
